Technology
Health
Medical

Viveve

$0.942
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.008 (-0.84%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell Viveve and other stocks, options, ETFs, and crypto commission-free!

About

Viveve Medical, Inc. engages in the provision of health products. Its activities include development and distribution of women's health solutions. Read More Its products include non-surgical, non-ablative medical device that remodels collagen and restores vaginal tissue. The company was founded on March 3, 1987 and is headquartered Englewood, CO.

Employees
67
Headquarters
Englewood, Colorado
Founded
1987
Market Cap
44.05M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
325.53K
High Today
$1.00
Low Today
$0.9301
Open Price
$0.94
Volume
31.57K
52 Week High
$4.34
52 Week Low
$0.8745

Collections

Technology
Health
Medical
2016 IPO
US
North America

News

Seeking AlphaMar 15

Viveve Medical, Inc. (VIVE) CEO Scott Durbin on Q4 2018 Results - Earnings Call Transcript

Viveve Medical, Inc. (NASDAQ:VIVE) Q4 2018 Earnings Conference Call March 14, 2019 5:00 PM ET Company Participants Scott Durbin - CEO Jeannie Swindle - Senior Director of Corporate Communications Conference Call Participants Josh Jennings - Cowen Matt Wizman - Raymond James Jonathan Block - Stifel Anthony Vendetti - Maxim Group Jeffrey Cohen - Ladenburg Thalmann Suraj Kalia - Northland Securities Matt Hewitt - Craig-Hallum Operator Good afternoon and welcome to the Viveve Fourth Quarter 2018 Fi...

286
Seeking AlphaMar 11

Viveve completes enrollment in VIVEVE II trial

Viveve Medical (NASDAQ:VIVE) has completed enrollment in its VIVEVE II trial, a randomized, double-blinded study to evaluate the safety and efficacy of its cryogen-cooled monopolar radiofrequency (CMRF) technology for the improvement of sexual function in women following vaginal childbirth.

253
MarketBeatFeb 26

Stock Price, News, & Analysis for Viveve Medical

Press coverage about VIVE stock has been trending negative this week, InfoTrie Sentiment reports. The research firm identifies negative and positive press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Viveve Medical earned a media sentiment score of -2.1 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 4.0 out of 10, mean...

180

Earnings

-$0.54
-$0.47
-$0.40
-$0.33
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
-$0.35 per share
Actual
-$0.38 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.